| Mechanisms controlling the function and life span of the corpus luteum GD Niswender, JL Juengel, PJ Silva, MK Rollyson, EW McIntush Physiological reviews 80 (1), 1-29, 2000 | 1435 | 2000 |
| Prostaglandin Metabolism in the Ovine Corpus Luteum: Catabolism of Prostaglandin F2α (PGF2α) Coincides with Resistance of the Corpus Luteum to PGF2α PJ Silva, JL Juengel, MK Rollyson, GD Niswender Biology of Reproduction 63 (5), 1229-1236, 2000 | 115 | 2000 |
| Messenger Ribonucleic Acid Encoding Monocyte Chemoattractant Protein-1 is Expressed by the Ovine Corpus Luteum in Response to Prostaglandin F2α J David Haworth, M Keith Rollyson, P Silva, EW McIntush, GD Niswender Biology of reproduction 58 (1), 169-174, 1998 | 52 | 1998 |
| Effect of Dose of Prostaglandin F2α on Steroidogenic Components and Oligonucleosomes in Ovine Luteal Tissue JL Juengel, JD Haworth, MK Rollyson, PJ Silva, HR Sawyer, ... Biology of reproduction 62 (4), 1047-1051, 2000 | 46 | 2000 |
| Academic medical centers as innovation ecosystems to address population–omics challenges in precision medicine PJ Silva, VM Schaibley, KS Ramos Journal of Translational Medicine 16, 1-12, 2018 | 21 | 2018 |
| Academic Medical Centers as Innovation Ecosystems: Evolution of Industry Partnership Models Beyond the Bayh–Dole Act PJ Silva, KS Ramos Academic Medicine 93 (8), 1135-1141, 2018 | 19 | 2018 |
| Implementation of pharmacogenomics and artificial intelligence tools for chronic disease management in primary care setting P Silva, D Jacobs, J Kriak, A Abu-Baker, G Udeani, G Neal, K Ramos Journal of Personalized Medicine 11 (6), 443, 2021 | 13 | 2021 |
| An idealized clinicogenomic registry to engage underrepresented populations using innovative technology P Silva, DV Dahlke, ML Smith, W Charles, J Gomez, MG Ory, KS Ramos Journal of Personalized Medicine 12 (5), 713, 2022 | 10 | 2022 |
| Health equity innovation in precision medicine: Current challenges and future directions MG Ory, OE Adepoju, KS Ramos, PS Silva, D Vollmer Dahlke Frontiers in Public Health 11, 1119736, 2023 | 3 | 2023 |
| Multianalyte tests in clinical care J Aponte, PJ Silva, KS Ramos Elsevier, 2023 | 2 | 2023 |
| Precision medicine at the academic-industry interface PJ Silva, KS Ramos Precision Medicine for Investigators, Practitioners and Providers, 545-560, 2020 | 2 | 2020 |
| Prostaglandin metabolism in the ovine corpus luteum PJ Silva Colorado State University, 1999 | 2 | 1999 |
| Maturing early-stage biomedical research; proof of concept program objectives, decision making and preliminary performance at the University of Colorado R Silva, DN Allen, RJ Traystman Medical innovation & business 1 (1), 52, 2009 | 1 | 2009 |
| Case Report: Life‑Threatening Fluoxetine‑Linked Postoperative Bleeding Informed by Pharmacogenetic Evaluation. KS Rogers, S, Silva, PJ, Udeani, G, Deleon, M, Mutyala, S, Panahi, L, Abu ... Drugs in R&D, 2023 | | 2023 |
| Proprietary Strategies in Precision Medicine S Wan, W, Silva P, Odenweller, D. Leeuwon Comprehensive Precision Medicine 1, 2023 | | 2023 |
| Chimeric cohorts and consortia can power and scale precision medicine PJ Silva, NK Sweitzer Elsevier, 2023 | | 2023 |
| Alternative evidence in drug development and regulatory science N Janjan, PJ Silva, KS Ramos, MG Ory, ML Smith Elsevier, 2023 | | 2023 |
| Cell therapy as precision medicine: Clinical, regulatory, and commercial lessons learned from advances in the islet and CAR-T fields PJ Silva, KK Papas Elsevier, 2023 | | 2023 |
| External control arms: COVID-19 reveals the merits of using real world evidence in real-time for clinical and public health investigations P Silva, N Janjan, KS Ramos, G Udeani, L Zhong, MG Ory, ML Smith Frontiers in Medicine 10, 2023 | | 2023 |
| Trends and implementation of preemptive pharmacogenomic testing PJ Silva, KS Ramos Elsevier, 2023 | | 2023 |
